$14.92
0.352.40%
At close: -
$14.92
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Travere Therapeutics Insider Trading Activity | NASDAQ:TVTX | Benzinga
Track the latest Travere Therapeutics insider trading activity. Stay informed on recent buys, sells, and market impact for Travere Therapeutics stock.
What is Insider Activity?
Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide valuable insights into their confidence in the company's future performance.
What are Travere Therapeutics Inc Insiders Doing?
At Travere Therapeutics Inc, recent insider activity has drawn attention. Over the last 30 days, insiders have reported selling a total of 48.00 shares worth $630.94, meanwhile, insiders have report no purchases in the last 30 days.
Notable Recent Insider Buys and Sales
- On April 14, 2025, Christopher Cline, the company's CHIEF FINANCIAL OFFICER sold 48 shares for $13.14 each.
- On January 23, 2025, Christopher Cline, the company's CHIEF FINANCIAL OFFICER sold 865 shares for $18.94 each.
- On January 23, 2025, Sandra Calvin, the company's SVP, CHIEF ACCOUNTING OFFICER sold 925 shares for $18.94 each.
Ownership Statistics for Travere Therapeutics Inc
Shares Outstanding
88.740M
Insider Shares Owned
4.103M
Insider Percentage Owned
4.62%
Institutional Shares Held
45.446M
Institutional Percentage Held
51.2%
| Apr 14, 2025 | Christopher Cline | CHIEF FINANCIAL OFFICER | -48.00 | $13.14 | -$630.94 | SELL | -0.05% | 89.99K | Apr 11 | View |
| Feb 12, 2025 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | 2.80K | $23.53 | -$122.36K | SELL-OPTIONS | 2.93% | 98.52K | Feb 10 - Feb 12 | View |
| Feb 12, 2025 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | 0.00 | $23.53 | -$188.24K | SELL-OPTIONS | 0.00% | 89.48K | Feb 10 - Feb 12 | View |
| Feb 12, 2025 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | -9.24K | $20.81 | -$607.90K | SELL | -14.52% | 54.41K | Feb 11 | View |
| Feb 12, 2025 | Peter Heerma | CHIEF COMMERCIAL OFFICER | 2.36K | $24.33 | -$137.28K | SELL-OPTIONS | 1.92% | 125.07K | Feb 10 - Feb 12 | View |
| Feb 12, 2025 | Eric Dube | CHIEF EXECUTIVE OFFICER | -11.38K | $24.04 | -$273.45K | SELL | -2.64% | 419.17K | Feb 11 | View |
| Feb 12, 2025 | Jula Inrig | CHIEF MEDICAL OFFICER | 5.43K | $23.53 | -$60.43K | SELL-OPTIONS | 6.45% | 89.60K | Feb 10 - Feb 12 | View |
| Feb 10, 2025 | Roy Baynes | — | 0.00 | $19.72 | -$45.60K | SELL-OPTIONS | 0.00% | 31.00K | Feb 06 | View |
| Feb 04, 2025 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | 12.55K | $19.78 | -$177.05K | GRANT | 15.09% | 95.72K | Jan 31 - Feb 03 | View |
| Feb 04, 2025 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | 12.55K | $19.78 | -$177.05K | GRANT | 16.31% | 89.48K | Jan 31 - Feb 03 | View |
| Feb 04, 2025 | Eric Dube | CHIEF EXECUTIVE OFFICER | 79.31K | $20.21 | -$1.02M | GRANT | 22.58% | 430.55K | Jan 31 - Feb 03 | View |
| Feb 04, 2025 | Jula Inrig | CHIEF MEDICAL OFFICER | 24.73K | $20.12 | -$106.08K | GRANT | 41.60% | 84.17K | Jan 31 - Feb 04 | View |
| Feb 04, 2025 | Peter Heerma | CHIEF COMMERCIAL OFFICER | 16.33K | $20.12 | -$103.94K | GRANT | 15.36% | 122.71K | Jan 31 - Feb 03 | View |
| Feb 04, 2025 | Christopher Cline | CHIEF FINANCIAL OFFICER | 16.31K | $20.12 | -$104.46K | GRANT | 22.12% | 90.04K | Jan 31 - Feb 03 | View |
| Feb 04, 2025 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 9.65K | $20.12 | -$67.36K | GRANT | 17.87% | 63.65K | Jan 31 - Feb 03 | View |
| Jan 23, 2025 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | -2.44K | $19.46 | -$47.42K | SELL | -2.85% | 83.17K | Jan 22 | View |
| Jan 23, 2025 | Eric Dube | CHIEF EXECUTIVE OFFICER | -10.74K | $19.46 | -$208.92K | SELL | -2.97% | 351.24K | Jan 22 | View |
| Jan 23, 2025 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | -2.44K | $19.46 | -$47.42K | SELL | -3.07% | 76.93K | Jan 22 | View |
| Jan 23, 2025 | Roy Baynes | — | 0.00 | $18.75 | -$40.00K | SELL-OPTIONS | 0.00% | 31.00K | Jan 23 | View |
| Jan 23, 2025 | Peter Heerma | CHIEF COMMERCIAL OFFICER | -1.58K | $18.94 | -$30.00K | SELL | -1.47% | 106.37K | Jan 22 | View |
| Jan 23, 2025 | Christopher Cline | CHIEF FINANCIAL OFFICER | -865.00 | $18.94 | -$16.38K | SELL | -1.16% | 73.73K | Jan 22 | View |
| Jan 23, 2025 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | -925.00 | $18.94 | -$17.52K | SELL | -1.68% | 54.00K | Jan 22 | View |
| Jan 06, 2025 | Jula Inrig | CHIEF MEDICAL OFFICER | -2.51K | $19.04 | -$47.72K | SELL | -4.05% | 59.44K | Jan 03 - Jan 06 | View |
| Dec 27, 2024 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 0.00 | $14.94 | -$68.23K | SELL-OPTIONS | 0.00% | 54.93K | Dec 26 | View |
| Nov 25, 2024 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 2.91K | $15.49 | -$31.21K | SELL-OPTIONS | 5.59% | 54.93K | Nov 25 | View |
| Oct 04, 2024 | GARY LYONS | — | 0.00 | $12.60 | -$169.90K | SELL-OPTIONS | 0.00% | 51.00K | Oct 04 | View |
| Sep 30, 2024 | Jeffrey Meckler | — | 0.00 | $12.27 | -$143.12K | SELL-OPTIONS | 0.00% | 81.00K | Sep 30 | View |
| Sep 10, 2024 | Jula Inrig | CHIEF MEDICAL OFFICER | -684.00 | $12.98 | -$8.88K | SELL | -1.09% | 61.95K | Sep 10 | View |
| Sep 09, 2024 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | 2.36K | $11.52 | -$50.54K | GRANT | 2.88% | 84.45K | Sep 05 - Sep 09 | View |
| Sep 09, 2024 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | 2.36K | $11.52 | -$50.54K | GRANT | 3.10% | 78.63K | Sep 05 - Sep 09 | View |
| Sep 09, 2024 | Eric Dube | CHIEF EXECUTIVE OFFICER | 11.38K | $11.52 | -$243.36K | GRANT | 3.24% | 361.98K | Sep 05 - Sep 09 | View |
| Sep 09, 2024 | Jula Inrig | CHIEF MEDICAL OFFICER | 4.56K | $11.52 | -$25.24K | GRANT | 7.85% | 62.63K | Sep 05 - Sep 09 | View |
| Sep 09, 2024 | Peter Heerma | CHIEF COMMERCIAL OFFICER | 4.56K | $11.52 | -$25.24K | GRANT | 4.41% | 107.96K | Sep 05 - Sep 09 | View |
| Sep 09, 2024 | Christopher Cline | CHIEF FINANCIAL OFFICER | 4.26K | $11.52 | -$28.68K | GRANT | 6.06% | 74.59K | Sep 05 - Sep 09 | View |
| Sep 05, 2024 | Christopher Cline | CHIEF FINANCIAL OFFICER | -514.00 | $9.51 | -$4.89K | SELL | -0.73% | 70.33K | Sep 04 | View |
| Apr 12, 2024 | Christopher Cline | CHIEF FINANCIAL OFFICER | -54.00 | $6.74 | -$363.96 | SELL | -0.08% | 70.85K | Apr 11 | View |
| Feb 02, 2024 | Eric Dube | CHIEF EXECUTIVE OFFICER | 115.88K | $8.70 | -$166.44K | GRANT | 49.37% | 350.60K | Jan 31 - Feb 01 | View |
| Feb 02, 2024 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | 20.24K | $8.71 | -$41.50K | GRANT | 33.46% | 80.72K | Jan 31 - Feb 01 | View |
| Feb 02, 2024 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 10.68K | $8.53 | -$24.06K | GRANT | 25.84% | 52.02K | Jan 31 - Feb 01 | View |
| Feb 02, 2024 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | 20.24K | $8.71 | -$41.50K | GRANT | 36.11% | 76.27K | Jan 31 - Feb 01 | View |
| Feb 02, 2024 | Peter Heerma | CHIEF COMMERCIAL OFFICER | 20.80K | $8.53 | -$35.79K | GRANT | 26.44% | 99.50K | Jan 31 - Feb 01 | View |
| Feb 02, 2024 | Jula Inrig | CHIEF MEDICAL OFFICER | 22.83K | $8.53 | -$18.55K | GRANT | 64.76% | 58.07K | Jan 31 - Feb 01 | View |
| Feb 02, 2024 | Christopher Cline | CHIEF FINANCIAL OFFICER | 21.18K | $8.53 | -$32.57K | GRANT | 42.60% | 70.90K | Jan 31 - Feb 01 | View |
| Jan 25, 2024 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | -2.06K | $8.96 | -$18.48K | SELL | -3.55% | 56.03K | Jan 23 | View |
| Jan 25, 2024 | Eric Dube | CHIEF EXECUTIVE OFFICER | -7.87K | $8.96 | -$70.54K | SELL | -3.25% | 234.72K | Jan 23 | View |
| Jan 25, 2024 | Christopher Cline | CHIEF FINANCIAL OFFICER | -853.00 | $9.07 | -$7.74K | SELL | -1.69% | 49.72K | Jan 23 | View |
| Jan 25, 2024 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | -2.06K | $8.96 | -$18.48K | SELL | -3.30% | 60.48K | Jan 23 | View |
| Jan 25, 2024 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | -910.00 | $9.07 | -$8.25K | SELL | -2.15% | 41.34K | Jan 23 | View |
| Jan 25, 2024 | Peter Heerma | CHIEF COMMERCIAL OFFICER | -1.56K | $9.07 | -$14.14K | SELL | -1.94% | 78.70K | Jan 23 | View |
| Jan 05, 2024 | Jula Inrig | CHIEF MEDICAL OFFICER | -2.51K | $9.43 | -$23.65K | SELL | -6.65% | 35.25K | Jan 03 - Jan 04 | View |
| Oct 04, 2023 | Peter Heerma | CHIEF COMMERCIAL OFFICER | -3.09K | $8.25 | -$25.50K | SELL | -3.71% | 80.26K | Oct 03 | View |
| Sep 05, 2023 | Christopher Cline | CHIEF FINANCIAL OFFICER | -457.00 | $14.71 | -$6.72K | SELL | -0.90% | 50.57K | Sep 05 | View |
| Sep 05, 2023 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | 1.49K | $14.71 | -$26.70K | GRANT | 2.49% | 61.17K | Aug 31 - Sep 05 | View |
| Sep 05, 2023 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | 1.49K | $14.71 | -$26.70K | GRANT | 2.62% | 58.10K | Aug 31 - Sep 05 | View |
| Sep 05, 2023 | Eric Dube | CHIEF EXECUTIVE OFFICER | 5.45K | $14.71 | -$65.53K | GRANT | 2.30% | 242.59K | Aug 31 - Sep 05 | View |
| May 12, 2023 | Christopher Cline | CHIEF FINANCIAL OFFICER | -455.00 | $16.59 | -$7.55K | SELL | -0.88% | 51.03K | May 10 | View |
| May 12, 2023 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | -825.00 | $16.59 | -$13.69K | SELL | -1.44% | 56.61K | May 10 | View |
| May 12, 2023 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | -825.00 | $16.59 | -$13.69K | SELL | -1.37% | 59.21K | May 10 | View |
| May 12, 2023 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | -558.00 | $16.49 | -$9.20K | SELL | -1.30% | 42.25K | May 10 - May 11 | View |
| Apr 13, 2023 | Christopher Cline | CHIEF FINANCIAL OFFICER | -47.00 | $21.49 | -$1.01K | SELL | -0.09% | 51.49K | Apr 11 | View |
| Feb 02, 2023 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | 17.66K | $22.25 | -$57.63K | GRANT | 44.40% | 57.44K | Jan 31 - Feb 01 | View |
| Feb 02, 2023 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | 17.66K | $22.25 | -$57.63K | GRANT | 41.67% | 60.04K | Jan 31 - Feb 01 | View |
| Feb 02, 2023 | Peter Heerma | CHIEF COMMERCIAL OFFICER | 18.47K | $21.75 | -$38.70K | GRANT | 29.04% | 82.07K | Jan 31 - Feb 01 | View |
| Feb 02, 2023 | Christopher Cline | CHIEF FINANCIAL OFFICER | 18.66K | $21.75 | -$34.54K | GRANT | 56.77% | 51.53K | Jan 31 - Feb 01 | View |
| Feb 02, 2023 | Eric Dube | CHIEF EXECUTIVE OFFICER | 89.30K | $22.25 | -$182.36K | GRANT | 60.40% | 237.15K | Jan 31 - Feb 01 | View |
| Feb 02, 2023 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | 7.97K | $21.87 | -$44.42K | GRANT | 22.88% | 42.80K | Jan 31 - Feb 02 | View |
| Jan 26, 2023 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | -1.10K | $21.86 | -$23.98K | SELL | -3.05% | 34.84K | Jan 24 - Jan 25 | View |
| Jan 26, 2023 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | -2.06K | $21.50 | -$44.33K | SELL | -4.64% | 42.38K | Jan 24 | View |
| Jan 26, 2023 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | -2.06K | $21.50 | -$44.33K | SELL | -4.93% | 39.78K | Jan 24 | View |
| Jan 26, 2023 | Eric Dube | CHIEF EXECUTIVE OFFICER | -6.44K | $21.50 | -$138.50K | SELL | -4.18% | 147.85K | Jan 24 | View |
| Jan 26, 2023 | Christopher Cline | CHIEF FINANCIAL OFFICER | -852.00 | $21.90 | -$18.66K | SELL | -2.53% | 32.87K | Jan 24 | View |
| Jan 26, 2023 | Peter Heerma | CHIEF COMMERCIAL OFFICER | -1.55K | $21.90 | -$33.95K | SELL | -2.38% | 63.60K | Jan 24 | View |
| Jan 06, 2023 | Eric Dube | CHIEF EXECUTIVE OFFICER | -5.63K | $20.75 | -$116.72K | SELL | -3.52% | 154.29K | Jan 05 | View |
| Jan 06, 2023 | Jula Inrig | CHIEF MEDICAL OFFICER | -2.49K | $20.75 | -$51.73K | SELL | -12.46% | 17.51K | Jan 04 - Jan 05 | View |
| Oct 06, 2022 | Peter Heerma | CHIEF COMMERCIAL OFFICER | -3.04K | $25.68 | -$78.12K | SELL | -4.46% | 65.15K | Oct 04 | View |
| Sep 15, 2022 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | -349.00 | $28.00 | -$9.77K | SELL | -0.96% | 35.93K | Sep 13 | View |
| May 12, 2022 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | -1.56K | $21.71 | -$33.94K | SELL | -3.46% | 43.67K | May 11 | View |
| May 12, 2022 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | -1.95K | $21.51 | -$41.94K | SELL | -4.45% | 41.84K | May 10 - May 12 | View |
| May 12, 2022 | Laura Clague | CHIEF FINANCIAL OFFICER | -2.20K | $21.51 | -$47.32K | SELL | -5.81% | 35.66K | May 10 - May 11 | View |
| May 12, 2022 | Sandra Calvin | SVP, CHIEF ACCOUNTING OFFICER | -881.00 | $21.72 | -$19.13K | SELL | -2.41% | 35.73K | May 10 - May 11 | View |
| May 12, 2022 | STEVE ASELAGE | DIRECTOR | -2.58K | $21.92 | -$56.46K | SELL | -1.72% | 146.92K | May 11 | View |
| Feb 11, 2022 | Eric Dube | CHIEF EXECUTIVE OFFICER | -4.83K | $27.84 | -$134.52K | SELL | -2.93% | 159.91K | Feb 10 | View |
| Feb 02, 2022 | Sandra Calvin | VP, CORP CONTROLLER AND CAO | 7.95K | $26.51 | -$21.15K | GRANT | 27.74% | 36.61K | Jan 31 | View |
| Feb 02, 2022 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | 8.49K | $27.40 | -$36.99K | GRANT | 24.05% | 43.79K | Jan 31 | View |
| Feb 02, 2022 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | 8.71K | $27.40 | -$30.82K | GRANT | 23.86% | 45.23K | Jan 31 | View |
| Feb 02, 2022 | Peter Heerma | CHIEF COMMERCIAL OFFICER | 8.71K | $27.40 | -$30.82K | GRANT | 14.88% | 67.30K | Jan 31 | View |
| Feb 02, 2022 | Laura Clague | CHIEF FINANCIAL OFFICER | 8.60K | $27.40 | -$33.92K | GRANT | 29.41% | 37.85K | Jan 31 | View |
| Feb 02, 2022 | Eric Dube | CHIEF EXECUTIVE OFFICER | 33.03K | $27.40 | -$131.88K | GRANT | 25.08% | 164.75K | Jan 31 | View |
| Jan 26, 2022 | Sandra Calvin | VP, CORP CONTROLLER AND CAO | -934.00 | $24.58 | -$22.95K | SELL | -3.16% | 28.66K | Jan 24 | View |
| Jan 26, 2022 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | -1.88K | $24.98 | -$46.84K | SELL | -4.88% | 36.52K | Jan 24 | View |
| Jan 26, 2022 | Peter Heerma | CHIEF COMMERCIAL OFFICER | -1.88K | $24.98 | -$46.84K | SELL | -3.10% | 58.58K | Jan 24 | View |
| Jan 26, 2022 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | -2.25K | $24.98 | -$56.20K | SELL | -5.99% | 35.30K | Jan 24 | View |
| Jan 26, 2022 | Laura Clague | CHIEF FINANCIAL OFFICER | -2.06K | $24.98 | -$51.53K | SELL | -6.59% | 29.25K | Jan 24 | View |
| Jan 26, 2022 | Eric Dube | CHIEF EXECUTIVE OFFICER | -7.87K | $24.98 | -$196.67K | SELL | -5.64% | 131.71K | Jan 24 | View |
| Jan 12, 2022 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | 0.00 | $27.40 | -$137.00K | GRANT | 0.00% | 37.55K | Jan 10 - Jan 11 | View |
| Jan 12, 2022 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | 2.50K | $27.40 | -$68.50K | GRANT | 6.96% | 38.40K | Jan 10 - Jan 11 | View |
| Jan 12, 2022 | Laura Clague | CHIEF FINANCIAL OFFICER | 0.00 | $27.40 | -$205.50K | GRANT | 0.00% | 31.32K | Jan 10 - Jan 11 | View |
| Jan 06, 2022 | Eric Dube | CHIEF EXECUTIVE OFFICER | -17.33K | $30.08 | -$521.41K | SELL | -11.05% | 139.58K | Jan 04 - Jan 05 | View |
| Nov 18, 2021 | STEVE ASELAGE | DIRECTOR | -31.80K | $29.39 | -$934.60K | SELL | -17.54% | 149.49K | Nov 16 | View |
| Nov 09, 2021 | STEVE ASELAGE | DIRECTOR | 0.00 | $21.23 | -$100.00K | SELL-OPTIONS | 0.00% | 181.29K | Nov 05 | View |
| Nov 03, 2021 | STEVE ASELAGE | DIRECTOR | -8.50K | $29.69 | -$252.40K | SELL | -30.36% | 19.50K | Feb 04 - Nov 02 | View |
| Oct 08, 2021 | STEVE ASELAGE | DIRECTOR | 0.00 | $21.24 | -$600.96K | SELL-OPTIONS | 0.00% | 189.79K | Oct 07 | View |
| Oct 05, 2021 | Peter Heerma | CHIEF COMMERCIAL OFFICER | -3.06K | $24.77 | -$75.75K | SELL | -4.81% | 60.46K | Oct 04 | View |
| Aug 17, 2021 | Peter Heerma | CHIEF COMMERCIAL OFFICER | 3.09K | $17.12 | -$24.09K | GRANT | 5.12% | 63.52K | Aug 13 - Aug 17 | View |
| Aug 17, 2021 | Eric Dube | CHIEF EXECUTIVE OFFICER | 9.66K | $17.12 | -$134.14K | GRANT | 6.56% | 156.91K | Aug 13 - Aug 17 | View |
| Aug 17, 2021 | Noah Rosenberg | CHIEF MEDICAL OFFICER | 3.09K | $17.12 | -$24.09K | GRANT | 6.95% | 47.61K | Aug 13 - Aug 17 | View |
| Aug 17, 2021 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | 3.09K | $17.12 | -$24.09K | GRANT | 9.48% | 35.73K | Aug 13 - Aug 17 | View |
| Aug 17, 2021 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | 3.09K | $17.12 | -$24.09K | GRANT | 8.98% | 37.55K | Aug 13 - Aug 17 | View |
| Aug 17, 2021 | Laura Clague | CHIEF FINANCIAL OFFICER | 3.09K | $17.12 | -$24.09K | GRANT | 10.96% | 31.32K | Aug 13 - Aug 17 | View |
| Jul 29, 2021 | Noah Rosenberg | CHIEF MEDICAL OFFICER | -1.25K | $13.81 | -$17.26K | SELL | -2.73% | 44.52K | Jul 28 | View |
| Jun 03, 2021 | Eric Dube | CHIEF EXECUTIVE OFFICER | -9.56K | $14.62 | -$139.80K | SELL | -6.10% | 147.25K | Jun 01 - Jun 02 | View |
| May 13, 2021 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | -3.13K | $19.30 | -$60.31K | SELL | -8.97% | 31.71K | May 11 - May 12 | View |
| May 13, 2021 | Noah Rosenberg | CHIEF MEDICAL OFFICER | -750.00 | $19.30 | -$14.47K | SELL | -1.62% | 45.59K | May 11 - May 12 | View |
| May 13, 2021 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | -3.25K | $19.30 | -$62.73K | SELL | -8.62% | 34.45K | May 11 - May 12 | View |
| May 13, 2021 | Laura Clague | CHIEF FINANCIAL OFFICER | -4.00K | $19.30 | -$77.20K | SELL | -12.41% | 28.22K | May 11 - May 12 | View |
| May 13, 2021 | STEVE ASELAGE | DIRECTOR | -2.15K | $19.58 | -$42.02K | SELL | -1.14% | 186.79K | May 11 | View |
| Apr 20, 2021 | STEVE ASELAGE | DIRECTOR | 0.00 | $21.23 | -$100.00K | SELL-OPTIONS | 0.00% | 188.94K | Apr 16 | View |
| Mar 19, 2021 | STEVE ASELAGE | DIRECTOR | -7.73K | $21.84 | -$324.16K | SELL | -3.93% | 188.94K | Mar 17 | View |
| Feb 18, 2021 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | -2.50K | $28.01 | -$70.03K | SELL | -6.70% | 34.83K | Feb 17 - Feb 18 | View |
| Feb 09, 2021 | Noah Rosenberg | CHIEF MEDICAL OFFICER | -2.25K | $31.50 | -$70.86K | SELL | -4.63% | 46.34K | Feb 05 - Feb 08 | View |
| Feb 09, 2021 | Peter Heerma | CHIEF COMMERCIAL OFFICER | -2.25K | $31.50 | -$70.86K | SELL | -3.65% | 59.34K | Feb 05 - Feb 08 | View |
| Feb 09, 2021 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | -4.50K | $31.50 | -$141.73K | SELL | -10.76% | 37.33K | Feb 05 - Feb 08 | View |
| Feb 09, 2021 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | -4.50K | $31.50 | -$141.73K | SELL | -10.66% | 37.70K | Feb 05 - Feb 08 | View |
| Feb 09, 2021 | Laura Clague | CHIEF FINANCIAL OFFICER | -4.50K | $31.50 | -$141.73K | SELL | -12.25% | 32.22K | Feb 05 - Feb 08 | View |
| Feb 09, 2021 | Eric Dube | CHIEF EXECUTIVE OFFICER | -9.63K | $31.50 | -$303.17K | SELL | -5.78% | 156.81K | Feb 05 - Feb 08 | View |
| Feb 03, 2021 | Peter Heerma | CHIEF COMMERCIAL OFFICER | -1.13K | $29.83 | -$33.59K | SELL | -1.93% | 57.09K | Feb 02 - Feb 03 | View |
| Feb 03, 2021 | Noah Rosenberg | CHIEF MEDICAL OFFICER | -1.81K | $28.91 | -$52.41K | SELL | -3.95% | 44.09K | Feb 03 | View |
| Feb 03, 2021 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | -3.63K | $28.91 | -$104.80K | SELL | -8.85% | 37.33K | Feb 03 | View |
| Feb 03, 2021 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | -3.17K | $28.91 | -$91.79K | SELL | -7.77% | 37.70K | Feb 03 | View |
| Feb 03, 2021 | Laura Clague | CHIEF FINANCIAL OFFICER | -3.63K | $28.91 | -$104.80K | SELL | -10.11% | 32.22K | Feb 03 | View |
| Feb 03, 2021 | Eric Dube | CHIEF EXECUTIVE OFFICER | -2.41K | $28.91 | -$69.56K | SELL | -1.59% | 148.94K | Feb 03 | View |
| Feb 02, 2021 | Noah Rosenberg | CHIEF MEDICAL OFFICER | 3.19K | $30.75 | -$55.75K | GRANT | 7.46% | 45.91K | Jan 31 - Feb 02 | View |
| Feb 02, 2021 | WILLIAM ROTE | SENIOR VICE PRESIDENT, R&D | 1.38K | $30.75 | -$111.47K | GRANT | 3.27% | 43.46K | Jan 31 - Feb 02 | View |
| Feb 02, 2021 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | 1.82K | $30.75 | -$97.63K | GRANT | 4.67% | 40.88K | Jan 31 - Feb 02 | View |
| Feb 02, 2021 | Eric Dube | CHIEF EXECUTIVE OFFICER | 6.27K | $29.91 | -$261.27K | GRANT | 4.32% | 151.34K | Jan 31 - Feb 02 | View |
| Feb 02, 2021 | Laura Clague | CHIEF FINANCIAL OFFICER | 1.38K | $30.75 | -$111.47K | GRANT | 3.99% | 35.85K | Jan 31 - Feb 02 | View |
| Feb 02, 2021 | STEVE ASELAGE | DIRECTOR | 0.00 | $20.42 | -$516.50K | SELL-OPTIONS | 0.00% | 196.67K | Feb 02 | View |
| Jan 07, 2021 | Elizabeth E Reed | SVP, GC & CORPORATE SECRETARY | -1.38K | $26.83 | -$36.92K | SELL | -5.41% | 24.05K | Jan 05 - Jan 06 | View |
| Jan 07, 2021 | Eric Dube | CHIEF EXECUTIVE OFFICER | -6.88K | $26.83 | -$184.48K | SELL | -7.26% | 87.82K | Jan 05 - Jan 06 | View |
| Dec 16, 2020 | STEVE ASELAGE | — | -5.55K | $26.02 | -$144.38K | SELL | -2.74% | 196.67K | Dec 15 | View |
| Dec 04, 2020 | STEVE ASELAGE | — | -10.89K | $23.43 | -$184.85K | GIFT | -5.11% | 202.22K | Nov 19 - Dec 02 | View |
FAQ
Is insider trading legal?
Insider trading is legal so long as the insiders report those trades to the SEC. Illegal securities trading occurs when the insider is violating a fiduciary duty or fails to report their trades.
What are some examples of market manipulation?
Insider trading, pump and dump schemes, front running and wash trades are all examples of market manipulation. Investors who track insider asset movement should think carefully about why these insiders are trading their stocks before moving forward.
Browse insider trades on all stocks.
TVTX Insider Trading News
No news found
